{"filing":{"accession_number":"0001171843-26-004433","cik":"0001745114","ticker":"MOLN","company_name":"MOLECULAR PARTNERS AG","form":"6-K","filing_date":"2026-07-02","report_date":null,"primary_document":"f6k_070226.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1745114/000117184326004433/f6k_070226.htm"},"events":[{"id":15649,"run_id":13950,"accession_number":"0001171843-26-004433","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"This press release announces a clinical development milestone: the first patients dosed in a Phase 1/2a trial of MP0712, a Radio-DARPin candidate targeting DLL3 in small cell lung cancer and other neuroendocrine tumors. The disclosure is a material operational/clinical event for a clinical-stage biotech company, marking progress in a lead program under a strategic partnership with Orano Med. While not a discrete M\u0026A transaction, executive change, or financial event, it represents a significant advancement in the company's pipeline that would affect a reasonable investor's assessment of development progress and value.","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-07-02","form":"6-K","submitted_at":null,"items":[{"id":13513,"accession_number":"0001171843-26-004433","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a clinical development milestone: the first patients dosed in a Phase 1/2a trial of MP0712, a Radio-DARPin candidate targeting DLL3 in small cell lung cancer and other neuroendocrine tumors. The disclosure is a material operational/clinical event for a clinical-stage biotech company, marking progress in a lead program under a strategic partnership with Orano Med. While not a discrete M\u0026A transaction, executive change, or financial event, it represents a significant advancement in the company's pipeline that would affect a reasonable investor's assessment of development progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:07:44.388757+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":13513,"accession_number":"0001171843-26-004433","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"This press release announces a clinical development milestone: the first patients dosed in a Phase 1/2a trial of MP0712, a Radio-DARPin candidate targeting DLL3 in small cell lung cancer and other neuroendocrine tumors. The disclosure is a material operational/clinical event for a clinical-stage biotech company, marking progress in a lead program under a strategic partnership with Orano Med. While not a discrete M\u0026A transaction, executive change, or financial event, it represents a significant advancement in the company's pipeline that would affect a reasonable investor's assessment of development progress and value.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-02T10:07:44.388757+00:00","company_name":"MOLECULAR PARTNERS AG","ticker":"MOLN","filing_date":"2026-07-02"}]}